SEP 05, 2014 12:00 AM PDT

NSAIDs Stave Off Cancer Recurrence for Overweight Breast Cancer Patients, Study Finds

WRITTEN BY: Judy O'Rourke
Many adults may find popping a baby aspirin a day lessens the chance of a heart attack.

Researchers have now found that post-menopause, breast cancer patients who are overweight or obese, who incorporate hormone therapy into their treatment-and-who use nonsteroidal anti-inflammatory drugs (NSAIDs; eg, aspirin or ibuprofen) have a much lower rate of the cancer returning and a long interval should it return.

This subset of women has a relatively heightened risk of recurrence.

Their findings, published in the August 14 issue of Cancer Research, put forth a new option for lowering the incidence of breast cancer recurrence among this group of women.

Cancer researcher Linda deGraffenried, PhD, associate professor, School of Human Ecology, The University of Texas at Austin engineered the study in collaboration with Andrew Brenner, MD, an oncologist from the Cancer Therapy & Research Center, The University of Texas Health Science Center at San Antonio, and Murali Beeram, MD, a cancer specialist from the START Center for Cancer Care in San Antonio, Texas.

Employing a retrospective analysis of human subjects and cell cultures, the investigators found that NSAID use lowers the recurrence rate of the most common type of breast cancer-Er?-positive breast cancer--by 50 percent, and lengthens the duration of patients' disease-free interval by more than two years. ER-positive breast cancers, which multiply in response to exposure to the hormone estrogen, comprise about 75 percent of diagnoses.

The findings are preliminary, the researchers note, and further studies are being carried out to verify the results.

"Overweight or obese women diagnosed with breast cancer are facing a worse prognosis than normal-weight women," deGraffenried says. "We believe that obese women are facing a different disease. There are changes at the molecular level. We seek to modulate the disease promoting effects of obesity."

The researchers initially scoured medical records of 440 breast cancer patients, observing the prognoses of those who took NSAIDs versus those who did not.

The researchers created a second study to investigate how breast cancer cells act in the body. By immersing ER?-positive breast cancer cells in blood serum from obese women, they aimed to copy the conditions that encourage tumors to multiply, reproduce, and metastasize.

While the action that induces breast cancer in obese women to be more destructive and less receptive to treatment is not thoroughly understood, the researchers suggest that inflammation plays a key role. Their data also suggest inflammation negatively impacts the efficacy of aromatase inhibitors, a class of cancer drugs often prescribed to thwart cancer recurrence.

"Clinicians are finding that the five-year recurrence rate for postmenopausal women is much higher on aromatase inhibitors when the patient is obese," deGraffenried says. "We would like to identify which women are most likely to benefit from interventions like adding NSAIDs to treatment regimens."

Researcher Laura Bowers, The University of Texas at Austin, who oversaw the cell culture segment of the study, proposes that overweight or obese postmenopausal women - those at greater risk for breast cancer development - might profit from taking a low-dose aspirin daily. "What this study does is present great promise that a fairly inexpensive and nontoxic agent might benefit obese and overweight breast cancer patients who are at a higher risk of aromatase inhibitor failure - but further studies are needed to confirm these results," Bowers says.

An extended prospective study is on the drawing table to pinpoint disease biomarkers and keep track of patient response to the addition of NSAIDs to breast cancer treatment.
About the Author
  • Judy O'Rourke worked as a newspaper reporter before becoming chief editor of Clinical Lab Products magazine. As a freelance writer today, she is interested in finding the story behind the latest developments in medicine and science, and in learning what lies ahead.
You May Also Like
SEP 06, 2021
Drug Discovery & Development
Antibiotics Increase Colon Cancer Risk by 17%
SEP 06, 2021
Antibiotics Increase Colon Cancer Risk by 17%
People who take antibiotics are at an increased risk of developing colon cancer within five to ten years. The research w ...
NOV 01, 2021
Cancer
Gut Microbiota Promotes Resistance to Prostate Cancer Therapy
NOV 01, 2021
Gut Microbiota Promotes Resistance to Prostate Cancer Therapy
  The American Cancer Society estimates that nearly 250,000 men in the United States will be diagnosed with prostat ...
NOV 11, 2021
Clinical & Molecular DX
Cancer Pathologist Burnout? AI to the Rescue.
NOV 11, 2021
Cancer Pathologist Burnout? AI to the Rescue.
Diagnosing cancer is hard work. The challenging demands of their caseloads see diagnostic pathologists in many clinical ...
DEC 02, 2021
Cancer
A New Method to Enhance Immunotherapy in Mouse Tumors
DEC 02, 2021
A New Method to Enhance Immunotherapy in Mouse Tumors
Pancreatic ductal adenocarcinoma (PDAC) is the most common form of pancreatic cancer, accounting for about 90% of pancre ...
DEC 07, 2021
Immunology
Ancient Medicine and Synthetic Biology Collide to Combat Chemo Resistance
DEC 07, 2021
Ancient Medicine and Synthetic Biology Collide to Combat Chemo Resistance
  Strong chemical drugs used to obliterate all rapidly growing cells in the body have been used to treat cancer sin ...
DEC 16, 2021
Cancer
Age Matters! Young Adults May Need Different Cancer Therapies
DEC 16, 2021
Age Matters! Young Adults May Need Different Cancer Therapies
The incidence of various cancers, including multiple myeloma, colorectal, kidney, and pancreatic cancer, is steadily&nbs ...
Loading Comments...